The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Lee, J.S. | - |
dc.contributor.author | Kim, S.Y. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Kim, Y.J. | - |
dc.contributor.author | Kwon, K.A. | - |
dc.contributor.author | Park, D.K. | - |
dc.contributor.author | Chung, J.W. | - |
dc.date.available | 2020-02-27T12:43:32Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4358 | - |
dc.description.abstract | Background/Aims: Although some previous studies reported that a treatment combined with mucoprotective agent could improve the eradication rate in dual or triple therapy, there are other reports that question the efficacy of combining these drugs in concomitant therapy (CoCTx). The aim of this study was to investigate the effects of rebamipide or ecabet on the Helicobacter pylori (H. pylori) eradication combined with CoCTx. Methods: We retrospectively reviewed the medical records of 277 patients with proven H. pylori infection. They were assigned to one of 3 regimens for 10 days, twice daily: (a) CoCTx (n=118): lansoprazole 30 mg, amoxicillin 1 g, metronidazole 500 mg, and clarithromycin 500 mg; (b) CoCTx+rebamipide (100 mg) (n=85); (c) CoCTx+ecabet (1 g) (n=74). Results: The baseline characteristics were not significantly different. H. pylori eradication rates were 82.2% (97/118) in CoCTx, 90.6% (77/85) in CoCTx+rebamipide, and 89.2% (66/74) in CoCTx+ecabet (p=0.17), which were statistically insignificant. Overall adverse events were more frequently reported in the CoCTx+rebamipide (50.6%. 43/85) and CoCTx+ecabet (44.6%, 33/74) groups than in the CoCTx (32.2%, 38/118) (p = 0.03) group. Drug compliances were not different between three groups (CoCTx: 95.8%, 113/118; CoCT+rebamipide: 92.9%, 79/85; CoCTx+ecabet 98.6%,73/74) (p=0.209). Multivariate analysis showed that the risk of eradication failure was significantly increased with decreased drug compliance (odds ratio 3.52, 95% confidence interval 1.00-12.32; p=0.05). Conclusions: Addition of these mucoprotective agent was not superior to CoCTx alone for eradicating H. pylori infection with frequent adverse events. Rather, drug compliance is the most related factor affecting the eradication rate. Our data suggest the importance of drug compliance over the drugs used. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한소화기학회 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.title | The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen | - |
dc.title.alternative | 헬리코박터 파일로리 제균에서 10일 사제 동시 치료와 Rebamipide, Ecabet 추가 요법의 치료성적의 비교 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.4166/kjg.2018.71.4.204 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.71, no.4, pp.204 - 212 | - |
dc.identifier.kciid | ART002337479 | - |
dc.identifier.scopusid | 2-s2.0-85059798663 | - |
dc.citation.endPage | 212 | - |
dc.citation.startPage | 204 | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 71 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kim, J. | - |
dc.contributor.affiliatedAuthor | Kim, K. | - |
dc.contributor.affiliatedAuthor | Lee, J.S. | - |
dc.contributor.affiliatedAuthor | Kim, S.Y. | - |
dc.contributor.affiliatedAuthor | Kim, K. | - |
dc.contributor.affiliatedAuthor | Kim, Y.J. | - |
dc.contributor.affiliatedAuthor | Kwon, K.A. | - |
dc.contributor.affiliatedAuthor | Park, D.K. | - |
dc.contributor.affiliatedAuthor | Chung, J.W. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Ecabet sodium | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Rebamipide | - |
dc.subject.keywordAuthor | Therapeutics | - |
dc.subject.keywordPlus | abietane derivative | - |
dc.subject.keywordPlus | alanine | - |
dc.subject.keywordPlus | antiinfective agent | - |
dc.subject.keywordPlus | antiulcer agent | - |
dc.subject.keywordPlus | ecabet | - |
dc.subject.keywordPlus | proton pump inhibitor | - |
dc.subject.keywordPlus | quinolone derivative | - |
dc.subject.keywordPlus | rebamipide | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | analogs and derivatives | - |
dc.subject.keywordPlus | breath analysis | - |
dc.subject.keywordPlus | combination drug therapy | - |
dc.subject.keywordPlus | drug administration | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | Helicobacter infection | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | isolation and purification | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metabolism | - |
dc.subject.keywordPlus | microbiology | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | patient compliance | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Alanine | - |
dc.subject.keywordPlus | Anti-Bacterial Agents | - |
dc.subject.keywordPlus | Anti-Ulcer Agents | - |
dc.subject.keywordPlus | Breath Tests | - |
dc.subject.keywordPlus | Diterpenes, Abietane | - |
dc.subject.keywordPlus | Drug Administration Schedule | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Helicobacter Infections | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Patient Compliance | - |
dc.subject.keywordPlus | Proton Pump Inhibitors | - |
dc.subject.keywordPlus | Quinolones | - |
dc.subject.keywordPlus | Retrospective Studies | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.